Administration of a probiotic with peanut oral immunotherapy: A randomized trial
Mimi LK Tang, Anne-Louise Ponsonby, Francesca Orsini, Dean Tey, Marnie Robinson, Ee Lyn Su, Paul Licciardi, Wesley Burks, Susan Donath
Journal of Allergy and Clinical Immunology | MOSBY-ELSEVIER | Published : 2015
BACKGROUND: Coadministration of a bacterial adjuvant with oral immunotherapy (OIT) has been suggested as a potential treatment for food allergy. OBJECTIVE: To evaluate a combined therapy comprising a probiotic together with peanut OIT. METHODS: We performed a double-blind, placebo-controlled randomized trial of the probiotic Lactobacillus rhamnosus CGMCC 1.3724 and peanut OIT (probiotic and peanut oral immunotherapy [PPOIT]) in children (1-10 years) with peanut allergy. The primary outcome was induction of sustained unresponsiveness 2 to 5 weeks after discontinuation of treatment (referred to as possible sustained unresponsiveness). Secondary outcomes were desensitization, peanut skin prick ..View full abstract
Awarded by Murdoch Childrens Research Institute, Perpetual Philanthropy
Awarded by National Health and Medical Research Council Australia (NHMRC)
Supported by the Food Allergy and Anaphylaxis Network (FAAN), the Murdoch Childrens Research Institute, Perpetual Philanthropy (grant ID 493), the CASS Foundation, the Financial Markets Foundation for Children and the National Health and Medical Research Council Australia (NHMRC project grant no. 1029690). Nestle Health Science were provided a copy of the final draft before submission (as required by a Material Transfer Agreement).